PER 5.41% 7.8¢ percheron therapeutics limited

MS Cure - Monash Uni, page-13

  1. 164 Posts.
    lightbulb Created with Sketch. 28
    All in all I’m sure that ANP will still be putting ATL1102 forward for both MS and DMD. They still haven’t looked at what the potency of ATL1102 on MS would be at a higher dosage. It too may prove to be groundbreaking. Plus I think ANP is a little further down the road in relation to development and testing than Monash, and they are cashed up fairly well too. I’m sure ANP will be following this story closely being a Melbourne based company. GLTAH.
    Last edited by ROGErRAMJ3T: 18/02/20
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.8¢
Change
0.004(5.41%)
Mkt cap ! $68.96M
Open High Low Value Volume
7.5¢ 7.8¢ 7.5¢ $54.13K 715.7K

Buyers (Bids)

No. Vol. Price($)
5 122370 7.6¢
 

Sellers (Offers)

Price($) Vol. No.
7.8¢ 62682 2
View Market Depth
Last trade - 15.07pm 07/08/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.